247 related articles for article (PubMed ID: 32923150)
21. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
22. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.
Jiang YZ; Liu YR; Xu XE; Jin X; Hu X; Yu KD; Shao ZM
Cancer Res; 2016 Apr; 76(8):2105-14. PubMed ID: 26921339
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.
Gaceb H; Cherbal F; Bakour R; Ould-Rouis A; Mahfouf H
Pathol Oncol Res; 2018 Apr; 24(2):297-308. PubMed ID: 28478614
[TBL] [Abstract][Full Text] [Related]
25. A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer.
Huang R; Wang H; Hong J; Wang Z; Wu J; Huang O; He J; Chen W; Li Y; Chen X; Shen K
Front Pharmacol; 2023; 14():1191910. PubMed ID: 37251343
[No Abstract] [Full Text] [Related]
26. Development of an immune-related prognostic biomarker for triple-negative breast cancer.
Zhang Y; Wang Q; Yang WK; Wang YS; Zhou Q; Lin J; Wei XX; Liang T; Liu T; Fan WT; Liang L; Xu YN
Ann Med; 2022 Dec; 54(1):1212-1220. PubMed ID: 35481432
[No Abstract] [Full Text] [Related]
27. A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.
Qian J; Chen H; Ji X; Eisenberg R; Chakravarthy AB; Mayer IA; Massion PP
Sci Rep; 2017 Apr; 7():45828. PubMed ID: 28387221
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Munzone E; Gray KP; Fumagalli C; Guerini-Rocco E; Láng I; Ruhstaller T; Gianni L; Kammler R; Viale G; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Barberis M; Colleoni M
Breast Cancer Res Treat; 2018 Jul; 170(2):351-360. PubMed ID: 29589138
[TBL] [Abstract][Full Text] [Related]
30. Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.
Su D; Chi M; Wang S; Di S; Zhang H; Lu Q; Yu Y; Xiong Y; Wei H; Lv Y; Zuo Y; Yang L
Brief Funct Genomics; 2022 May; 21(3):188-201. PubMed ID: 35348574
[TBL] [Abstract][Full Text] [Related]
31. Prognosis Prediction Through an Integrated Analysis of Single-Cell and Bulk RNA-Sequencing Data in Triple-Negative Breast Cancer.
Wang X; Chen H
Front Genet; 2022; 13():928175. PubMed ID: 35846145
[No Abstract] [Full Text] [Related]
32. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
Conte B; Brasó-Maristany F; Hernández AR; Pascual T; Villacampa G; Schettini F; Vidal Losada MJ; Seguí E; Angelats L; Garcia-Fructuoso I; Gómez-Bravo R; Lorman-Carbó N; Paré L; Marín-Aguilera M; Martínez-Sáez O; Adamo B; Sanfeliu E; Fratini B; Falato C; Chic N; Vivancos A; Villagrasa P; Staaf J; Parker JS; Perou CM; Prat A
EBioMedicine; 2024 Apr; 102():105043. PubMed ID: 38447275
[TBL] [Abstract][Full Text] [Related]
33. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
34. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
35. A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma.
Li XC; Wang MY; Yang M; Dai HJ; Zhang BF; Wang W; Chu XL; Wang X; Zheng H; Niu RF; Zhang W; Chen KX
Ann Oncol; 2018 Apr; 29(4):938-944. PubMed ID: 29351612
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
Fan CN; Ma L; Liu N
J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
[TBL] [Abstract][Full Text] [Related]
37. Classification of triple-negative breast cancer based on pathway enrichment levels.
Liu Q; Wang X
Med Oncol; 2023 Apr; 40(6):157. PubMed ID: 37093316
[TBL] [Abstract][Full Text] [Related]
38. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
39. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
40. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X
Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
